These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7985544)

  • 1. Towards an immunotherapy for p185HER2 overexpressing tumors.
    Carter P; Rodrigues ML; Lewis GD; Figari I; Shalaby MR
    Adv Exp Med Biol; 1994; 353():83-94. PubMed ID: 7985544
    [No Abstract]   [Full Text] [Related]  

  • 2. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
    Wels W; Groner B; Hynes NE
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
    [No Abstract]   [Full Text] [Related]  

  • 3. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
    Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
    Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGF mutant receptor vIII as a molecular target in cancer therapy.
    Kuan CT; Wikstrand CJ; Bigner DD
    Endocr Relat Cancer; 2001 Jun; 8(2):83-96. PubMed ID: 11397666
    [No Abstract]   [Full Text] [Related]  

  • 8. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z; Lewis GD; Carter P
    Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.
    Park JW; Stagg R; Lewis GD; Carter P; Maneval D; Slamon DJ; Jaffe H; Shepard HM
    Cancer Treat Res; 1992; 61():193-211. PubMed ID: 1360232
    [No Abstract]   [Full Text] [Related]  

  • 10. Engineering antibodies for therapy.
    Presta LG
    Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.
    Dillman RO
    Cancer Biother Radiopharm; 1999 Feb; 14(1):5-10. PubMed ID: 10850281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
    Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
    Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies.
    Brinkmann U; Kontermann RE
    Science; 2021 May; 372(6545):916-917. PubMed ID: 34045345
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3.
    Knuth A; Bernhard H; Jäger E; Wölfel T; Karbach J; Jäggle C; Strittmatter W; Meyer zum Büschenfelde KH
    Eur J Cancer; 1994; 30A(8):1103-7. PubMed ID: 7654439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.